Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.86 (-1.42%)
AAPL   144.52 (-2.42%)
MSFT   241.12 (-2.57%)
META   108.74 (-2.40%)
GOOGL   96.12 (-1.37%)
AMZN   94.11 (+0.75%)
TSLA   182.92 (+0.03%)
NVDA   158.20 (-2.77%)
NIO   10.12 (-0.49%)
BABA   75.80 (+0.40%)
AMD   73.12 (-2.69%)
T   18.79 (-1.73%)
MU   55.74 (-4.57%)
CGC   3.41 (-6.83%)
F   13.73 (-2.49%)
GE   85.49 (-3.01%)
DIS   95.70 (-3.21%)
AMC   7.36 (-2.00%)
PYPL   79.88 (-0.25%)
PFE   49.58 (+0.75%)
NFLX   281.33 (-1.47%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.86 (-1.42%)
AAPL   144.52 (-2.42%)
MSFT   241.12 (-2.57%)
META   108.74 (-2.40%)
GOOGL   96.12 (-1.37%)
AMZN   94.11 (+0.75%)
TSLA   182.92 (+0.03%)
NVDA   158.20 (-2.77%)
NIO   10.12 (-0.49%)
BABA   75.80 (+0.40%)
AMD   73.12 (-2.69%)
T   18.79 (-1.73%)
MU   55.74 (-4.57%)
CGC   3.41 (-6.83%)
F   13.73 (-2.49%)
GE   85.49 (-3.01%)
DIS   95.70 (-3.21%)
AMC   7.36 (-2.00%)
PYPL   79.88 (-0.25%)
PFE   49.58 (+0.75%)
NFLX   281.33 (-1.47%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.86 (-1.42%)
AAPL   144.52 (-2.42%)
MSFT   241.12 (-2.57%)
META   108.74 (-2.40%)
GOOGL   96.12 (-1.37%)
AMZN   94.11 (+0.75%)
TSLA   182.92 (+0.03%)
NVDA   158.20 (-2.77%)
NIO   10.12 (-0.49%)
BABA   75.80 (+0.40%)
AMD   73.12 (-2.69%)
T   18.79 (-1.73%)
MU   55.74 (-4.57%)
CGC   3.41 (-6.83%)
F   13.73 (-2.49%)
GE   85.49 (-3.01%)
DIS   95.70 (-3.21%)
AMC   7.36 (-2.00%)
PYPL   79.88 (-0.25%)
PFE   49.58 (+0.75%)
NFLX   281.33 (-1.47%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.86 (-1.42%)
AAPL   144.52 (-2.42%)
MSFT   241.12 (-2.57%)
META   108.74 (-2.40%)
GOOGL   96.12 (-1.37%)
AMZN   94.11 (+0.75%)
TSLA   182.92 (+0.03%)
NVDA   158.20 (-2.77%)
NIO   10.12 (-0.49%)
BABA   75.80 (+0.40%)
AMD   73.12 (-2.69%)
T   18.79 (-1.73%)
MU   55.74 (-4.57%)
CGC   3.41 (-6.83%)
F   13.73 (-2.49%)
GE   85.49 (-3.01%)
DIS   95.70 (-3.21%)
AMC   7.36 (-2.00%)
PYPL   79.88 (-0.25%)
PFE   49.58 (+0.75%)
NFLX   281.33 (-1.47%)
NASDAQ:ALLK

Allakos - ALLK Stock Forecast, Price & News

$7.36
-0.08 (-1.08%)
(As of 11/28/2022 03:59 PM ET)
Add
Compare
Today's Range
$7.35
$7.61
50-Day Range
$5.16
$7.57
52-Week Range
$2.54
$11.73
Volume
27,368 shs
Average Volume
1.55 million shs
Market Capitalization
$627.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$62.00

Allakos MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
727.8% Upside
$62.00 Price Target
Short Interest
Healthy
4.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
0.48mentions of Allakos in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$20 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($5.18) to ($2.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.87 out of 5 stars

Medical Sector

82nd out of 1,040 stocks

Pharmaceutical Preparations Industry

35th out of 509 stocks

ALLK stock logo

About Allakos (NASDAQ:ALLK) Stock

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

ALLK Stock News Headlines

Why Is Allakos (ALLK) Stock Soaring 25% Today?
See More Headlines
Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

ALLK Company Calendar

Last Earnings
11/08/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALLK
Fax
N/A
Employees
192
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$62.00
High Stock Price Forecast
$155.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+742.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
10 Analysts

Profitability

Net Income
$-269,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.20 per share

Miscellaneous

Free Float
56,874,000
Market Cap
$627.10 million
Optionable
Not Optionable
Beta
0.41

Key Executives

  • Dr. Robert Alexander Ph.D.Dr. Robert Alexander Ph.D. (Age 52)
    CEO & Director
    Comp: $1.39M
  • Dr. Adam L. Tomasi Ph.D. (Age 52)
    Pres & COO
    Comp: $1.06M
  • Mr. Baird Radford III
    Chief Financial Officer
  • Dr. Henrik Sandvad Rasmussen (Age 63)
    Strategic Advisor
  • Dr. Craig Paterson M.D.
    Chief Medical Officer
  • Brad Youngblood
    Head of Research
  • Mr. Alan Chang
    Director of Medical Affairs & Data Analytics













ALLK Stock - Frequently Asked Questions

Should I buy or sell Allakos stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 2 sell ratings, 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.
View ALLK analyst ratings
or view top-rated stocks.

What is Allakos' stock price forecast for 2023?

10 Wall Street analysts have issued twelve-month price targets for Allakos' shares. Their ALLK share price forecasts range from $13.00 to $155.00. On average, they anticipate the company's share price to reach $62.00 in the next twelve months. This suggests a possible upside of 733.3% from the stock's current price.
View analysts price targets for ALLK
or view top-rated stocks among Wall Street analysts.

How have ALLK shares performed in 2022?

Allakos' stock was trading at $9.79 at the start of the year. Since then, ALLK shares have decreased by 24.0% and is now trading at $7.44.
View the best growth stocks for 2022 here
.

When is Allakos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our ALLK earnings forecast
.

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) issued its quarterly earnings results on Monday, November, 8th. The company reported ($1.16) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by $0.04.

What other stocks do shareholders of Allakos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

When did Allakos IPO?

(ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

What is Allakos' stock symbol?

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Who are Allakos' major shareholders?

Allakos' stock is owned by a variety of institutional and retail investors. Top institutional investors include NEA Management Company LLC (7.22%), Logos Global Management LP (6.97%), BVF Inc. IL (5.88%), Vivo Capital LLC (4.84%), Vanguard Group Inc. (3.65%) and BlackRock Inc. (2.54%). Insiders that own company stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends
.

How do I buy shares of Allakos?

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allakos' stock price today?

One share of ALLK stock can currently be purchased for approximately $7.44.

How much money does Allakos make?

Allakos (NASDAQ:ALLK) has a market capitalization of $633.92 million. The company earns $-269,860,000.00 in net income (profit) each year or ($6.76) on an earnings per share basis.

How many employees does Allakos have?

The company employs 192 workers across the globe.

How can I contact Allakos?

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for the company is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at ir@allakos.com.

This page (NASDAQ:ALLK) was last updated on 11/28/2022 by MarketBeat.com Staff